Chemoinformaics analysis of N-trans-Ferulolyltyramine
| Molecular Weight | 313.353 | nRot | 6 |
| Heavy Atom Molecular Weight | 294.201 | nRig | 14 |
| Exact Molecular Weight | 313.131 | nRing | 2 |
| Solubility: LogS | -3.054 | nHRing | 0 |
| Solubility: LogP | 2.538 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 42 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 2 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 19 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 18 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 12 |
| nHA | 4 | APOL | 47.0371 |
| nHD | 3 | BPOL | 22.2349 |
| QED | 0.716 |
| Synth | 1.987 |
| Natural Product Likeliness | 0.324 |
| NR-PPAR-gamma | 0.026 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.035 |
| Pgp-sub | 0.108 |
| HIA | 0.009 |
| CACO-2 | -4.86 |
| MDCK | 0.0000137 |
| BBB | 0.111 |
| PPB | 0.968329 |
| VDSS | 0.567 |
| FU | 0.0180034 |
| CYP1A2-inh | 0.88 |
| CYP1A2-sub | 0.789 |
| CYP2c19-inh | 0.736 |
| CYP2c19-sub | 0.095 |
| CYP2c9-inh | 0.742 |
| CYP2c9-sub | 0.947 |
| CYP2d6-inh | 0.739 |
| CYP2d6-sub | 0.905 |
| CYP3a4-inh | 0.584 |
| CYP3a4-sub | 0.321 |
| CL | 12.482 |
| T12 | 0.929 |
| hERG | 0.255 |
| Ames | 0.228 |
| ROA | 0.269 |
| SkinSen | 0.94 |
| Carcinogencity | 0.507 |
| EI | 0.113 |
| Respiratory | 0.475 |
| NR-Aromatase | 0.246 |
| Antiviral | Yes |
| Prediction | 0.543169 |